SCHEMBL3075424

SCHEMBL3075424

CC(=O)N[C@H]1CC[C@H](CCN2CCC(Oc3cccc(Cl)c3Cl)CC2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 13/20 0.55
DRD3 P35462 11/20 0.55
HTR1A P08908 3/20 0.54
DRD4 P21917 3/20 0.54
HTR2A P28223 3/20 0.54
HTR2C P28335 3/20 0.54
ADRA2A P08913 2/20 0.54
HTR7 P34969 2/20 0.54
ADRA1A P35348 2/20 0.54
HRH1 P35367 2/20 0.54
DRD1 P21728 2/20 0.54
HTR2B P41595 2/20 0.54
ABCB11 O95342 1/20 0.54
CHRM2 P08172 1/20 0.54
CHRM1 P11229 1/20 0.54
DRD5 P21918 1/20 0.54
KCNH2 Q12809 1/20 0.54
CHRM4 P08173 1/20 0.53
ADRB1 P08588 1/20 0.53
CHRM5 P08912 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14715658 1.00 DRD2 (0.55) DRD2DRD3HTR1ADRD4HTR2A
SCHEMBL14715653 0.89 DRD2 (0.55) DRD2DRD3HTR1ADRD4HTR2A
SCHEMBL3083298 0.88 DRD2 (0.66) DRD2DRD3HTR1ADRD4HTR2A
SCHEMBL3087153 0.88 DRD2 (0.50) DRD2DRD3HTR1ADRD4HTR2A
SCHEMBL14715613 0.88 DRD2 (0.50) DRD2DRD3HTR1ADRD4HTR2A
SCHEMBL14715659 0.87 DRD3 (0.72) DRD2DRD3HTR1ADRD4HTR2A
SCHEMBL3079766 0.87 DRD3 (0.72) DRD2DRD3HTR1ADRD4HTR2A
SCHEMBL3093404 0.86 DRD3 (0.58) DRD2DRD3HTR2A
SCHEMBL14715668 0.85 DRD2 (0.53) DRD2DRD3HTR1ADRD4HTR2A
SCHEMBL14715601 0.84 DRD3 (0.55) DRD2DRD3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079693-B1 ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HOFFMANN LA ROCHE (CH) 2013-02-27 EP claimed
US-7795437-B2 Ether derivatives HOFFMANN-LA ROCHE INC. (US) 2010-09-14 US claimed
EP-2079693-B1 ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HOFFMANN LA ROCHE (CH) 2013-02-27 EP disclosed
US-7795437-B2 Ether derivatives HOFFMANN-LA ROCHE INC. (US) 2010-09-14 US disclosed
US-20080103174-A1 ETHER DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103174-A1 ETHER DERIVATIVES GABRE, BDNF, ADH1A DRD2 59/4885DRD3 71/4885HTR1A 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.